Tuberculosis is one of the most common severe infections seen in patients receiving tumor necrosis factor inhibitors, and nontuberculous mycobacterial infection is an increasingly recognized condition in this setting. In this Review article, van Ingen et al. highlight the drug-related risks, clinical presentation, and screening and prevention of mycobacterial disease in patients undergoing treatment with biological agents.
- Jakko van Ingen
- Martin J Boeree
- Dick van Soolingen
